This is an observational imaging study to evaluate the value of multimodal [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging.~This research study involves:~Screening visit, and 1-3 study Multimodal [18F]DCFPyL PET/MRI visits~Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma)~It is expected that about 135 people will take part in this research study~The PET dye used in this study is called [18F]DCFPyL. [18F]DCFPyL is approved by the U.S. Food and Drug administration (FDA).~The PET/MRI scanner was approved by the U.S. FDA.
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.~This observational study involves [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)